Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast …

M Pegram, C Jackisch, SRD Johnston - NPJ Breast Cancer, 2023 - nature.com
The human epidermal growth factor receptor 2 (HER2) is overexpressed in 13–22% of
breast cancers (BC). Approximately 60–70% of HER2+ BC co-express hormone receptors …

Curcumin: modulator of key molecular signaling pathways in hormone-independent breast cancer

R Farghadani, R Naidu - Cancers, 2021 - mdpi.com
Simple Summary Breast cancer remains the most commonly diagnosed cancer and the
leading cause of cancer death among females worldwide. It is a highly heterogeneous …

[HTML][HTML] New insights into the functions of progesterone receptor (PR) isoforms and progesterone signaling

JM Azeez, TR Susmi, V Remadevi… - American journal of …, 2021 - ncbi.nlm.nih.gov
Progesterone, the ovarian steroid hormone, regulates a plentitude of biological processes in
tissues ranging from the brain to bones. Recognizing the role of progesterone and its …

Diagnostic accuracy and safety of 16α-[18F] fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients …

SY Chae, SH Ahn, SB Kim, S Han, SH Lee… - The Lancet …, 2019 - thelancet.com
Background A biopsy of first recurrence or metastatic disease is recommended to re-
evaluate oestrogen receptor status in patients with breast cancer and to select appropriate …

Rationally designed ruthenium complexes for breast cancer therapy

G Golbaghi, A Castonguay - Molecules, 2020 - mdpi.com
Since the discovery of the anticancer potential of ruthenium-based complexes, several
species were reported as promising candidates for the treatment of breast cancer, which …

[HTML][HTML] Heterogeneity in hormone-dependent breast cancer and therapy: steroid hormones, HER2, melanoma antigens, and cannabinoid receptors

TT Kunstič, N Debeljak, KF Tacer - Advances in Cancer Biology-Metastasis, 2023 - Elsevier
Breast cancer is the most frequently diagnosed cancer and the leading cause of death by
cancer among women worldwide. The prognosis of the disease and patients' response to …

Non-steroidal anti-inflammatory drugs and biomarkers: A new paradigm in colorectal cancer

G Rashid, NA Khan, D Elsori, A Rehman… - Frontiers in …, 2023 - frontiersin.org
Colorectal cancer is a sporadic, hereditary, or familial based disease in its origin, caused
due to diverse set of mutations in large intestinal epithelial cells. Colorectal cancer (CRC) is …

Progesterone receptors (PR) mediate STAT actions: PR and prolactin receptor signaling crosstalk in breast cancer models

KA Leehy, TH Truong, LJ Mauro, CA Lange - The Journal of steroid …, 2018 - Elsevier
Estrogen is the major mitogenic stimulus of mammary gland development during puberty
wherein ER signaling acts to induce abundant PR expression. PR signaling, in contrast, is …

FGF7/FGFR2–JunB signalling counteracts the effect of progesterone in luminal breast cancer

K Mieczkowski, K Kitowska, M Braun… - Molecular …, 2022 - Wiley Online Library
We have recently demonstrated that fibroblast growth factor receptor 2 (FGFR2)‐mediated
signalling alters progesterone receptor (PR) activity and response of oestrogen receptor α …

The inhibitory potency of isoxazole-curcumin analogue for the management of breast cancer: A comparative in vitro and molecular modeling investigation

FC Rodrigues, NVA Kumar, G Hari, KSR Pai, G Thakur - Chemical Papers, 2021 - Springer
Curcumin, a potent phytochemical derived from the spice element turmeric, has been
identified as a herbal remedy decades ago and has displayed promise in the field of …